
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind Corp is positioned for significant growth due to the potential approval of the Furoscix auto-injector, which may strengthen its product portfolio. The expectation of expanded labeling opportunities for the Tyvaso DPI, particularly in the context of treating pulmonary arterial hypertension (PAH), could further enhance the company's market presence and performance. Additionally, the strategic acquisition of SCPH is anticipated to bolster confidence in MannKind's capital allocation and may lead to higher peak sales forecasts, especially as interest in addressing patient needs outside of hospital settings grows.
Bears say
MannKind Corp's stock experienced significant weakness, declining 15.2%, likely due to the announcement of a competitive product from SQ Innovation priced at approximately 50% of MannKind's Furoscix, highlighting challenges in maintaining market share. Future sales projections for Afrezza are cautious, with estimates suggesting $127 million by 2030, contingent on successful market penetration, especially in the pediatric segment. Additionally, the company's pipeline assets MNKD-101 and MNKD-201 carry low probabilities of success (40% and 30%, respectively), reflecting inherent uncertainties in their development and commercialization strategies.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares